Introduction
Bacteriala nd protozoan infections are widely spread in some human populations.T he main burden of malaria and tuberculosis lies in resource-poor countries, for which,f or example, co-infection with human immunodeficiencyv irus (HIV) can dramatically increase the mortality rate. [1, 2] Moreover,i nt hese countries, drug compliance is often incomplete;t his leads to the emergence of drug-resistants trains of the pathogens, against which most of the available drugs are no longer effective. Therefore, there is an urgent need for the discoveryo f drugs with novel mechanisms of action that are able to overcome the issue of drug resistance. [3] The enzymes of the 2-C-methyl-d-erythritol-4-phosphate (MEP, 1)p athway for the biosynthesis of the essential isoprenoid precursors isopentenyl diphosphate (2)a nd dimethylallyl diphosphate (3)h ave been studied over the past decade as potentialt argets for the development of antimalarial and antituberculotic drugs (Scheme 1A). [4] The particulari nterest of medicinal chemists in these enzymes arises from the fact that the MEP pathway has been genetically validated as essential in multiple organisms, including Mycobacterium tuberculosis [5] and Plasmodium falciparum, [6] causativea gents of tuberculosis and malaria,r espectively,b ut is absenti nh umans, [7, 8] who exclusively utilize the alternative mevalonate pathway for the biosynthesis of 2 and 3. [9] This distinct taxonomic distribution sets the stage for the development of selective drugs targeting the enzymes of the MEP pathway. [10] An increasing number of inhibitors for the enzymes of the MEP pathway have been published, especially thanks to the growing number of crystal and co-crystal structures depositedi nt he RCSB Protein Data Bank, [11] with fosmidomycin-an inhibitor of the second enzymeo ft he pathway IspC-being the most successful example to date, given that it is the only inhibitor of the MEP pathway that is being investigated clinically,i nc ombination with piperaquine. [12] One of the least studied among the enzymeso ft he MEP pathway is 1-deoxy-d-xylulose-5-phosphate synthase (DXS), which catalyzes the first and rate-limiting steps of the MEP pathway,c onsisting in the thiamine-diphosphate (ThDP)-dependent decarboxylative condensation of pyruvate (4)a nd dglyceraldehyde-3-phosphate (5)t oa fford 1-deoxy-d-xylulose-5-phosphate (6) . Despite the high degree of sequence homology of the ThDP-binding site of DXS with other humanT hDPdependente nzymes [e.g.,t ransketolase( TK) or pyruvated ehyEnzymes of the 2-C-methyl-d-erythritol-4-phosphate pathway for the biosynthesis of isoprenoid precursorsa re validated drug targets. By performing phage display on 1-deoxy-d-xylulose-5-phosphate synthase (DXS),w hich catalyzes the first step of this pathway,w ed iscovered several peptide hits and recognized false-positive hits. The enriched peptide binder P12 emerged as as ubstrate (d-glyceraldehyde-3-phosphate)-competitivei nhibitor of Deinococcus radiodurans DXS. The results indicatep ossible overlap of the cofactor-and acceptor-substrate-binding pockets and providei nspiration for the design of inhibitors of DXS with au nique and novel mechanism of inhibition. drogenase (PDH);f or TK:2 0% sequence identityo verall, 47 % sequence identityi nt he ThDP-binding pocket between M. tuberculosis DXS and human TK], [13] DXS has distinctive features compared to mammalian ThDP-dependent enzymes, from both structurala nd kinetic points of view.I nf act, together with the peculiar domain arrangement, in which the particularly big ThDP-binding site is located within the same monomer, [14] DXS has au nique catalytic mechanism that involves the formationo faternary complex with substrates 4 and 5, [15] whereas all other ThDP-dependente nzymes follow classical ping-pong kinetics. [16] By taking advantage of these distinctive features, selectivei nhibition of DXS over human ThDP-dependent enzymess houldb ep ossible. The potentialo fD XS as a drug target is also underlined by its involvementi np yridoxal phosphate (vitamin B6) [17] and thiamine (vitamin B1) [18] biosynthesis in many bacteria, offering the opportunity to target three metabolic pathways at once. Furthermore, DXS possesses an important regulatory role for the flux of metabolites throughout the whole MEP pathway as shown recently. [19] Considering its crucial importance in bacterial metabolism, it is surprising that DXS is one of the least studied among the enzymeso ft he MEP pathway in terms of crystallography and inhibitord evelopment. In fact, there are just two crystal structures deposited in the PDB of the enzymei nc omplex with its cofactor ThDP (Escherichia coli,P DB ID:2 O1S, incomplete crystal structure; Deinococcus radiodurans,P DB ID:2 O1X). [14] The amino-acid residues lining the ThDP-binding pocket are highly conserved among the DXS enzymes in different organisms (e.g.,6 8% sequence identity in the ThDP-binding pocket and 38 %s equence identity overall between D. radiodurans and M. tuberculosis DXS). However,s trikingd ifferences in inhibitory potencyo ra ffinity have been observed upon evaluating ThDPcompetitive inhibitors against distinct orthologues.
[20] The herbicide ketoclomazone, for which no information aboutt he mode of inhibition (MOI) is available, is known to weakly inhibit Chlamydomonas DXS (IC 50 = 0.1mm), [21] whereas it is significantly more potent against Haemophilus influenzae DXS (K i = 23 mm). [22] Moreover,t he number of inhibitors for DXS reported in the literature to date (e.g., 7-11,S cheme 1B)i sv ery limited, as is the structural information about the corresponding binding modes. [4, [22] [23] [24] [25] [26] Phosphonates such as 10 have been shown to be pyruvate-competitivei nhibitors, with K i values in the low micromolar range against M. tuberculosis DXS and remarkable selectivity over mammalian ThDP-dependente nzymes. [25, 26] We recently reported fragment 11 to be am oderate inhibitor of D. radiodurans DXS (IC 50 = 595 mm)a nd validated its binding mode in solution by using acombination of NMR spectroscopy techniques. [13] All the inhibitors for DXS reported in the literature so far are small, organic molecules, but to our knowledge,t here is no reporto np eptidic inhibitors. Even thoughpeptides still partially suffer from a" deficiti ni mage", most of the limits associated with their development and optimization as therapeutic agents have been overcome in the past decade. The fact that peptideshave several advantages over small organic molecules encouragedm edicinal chemists to reconsider their potential as drug candidates. For example, the risk of systemic toxicity associated with their administration is reduced, and thanks to their short half-life, they do not tend to accumulate in tissues, with ar educed risk of complications causedb yt heir metabolites. [27] In addition, they offer the advantage that they can be effectively selected to bind functional sites of target enzymes with high specificity. [28, 29] Moreover,m ultiple peptides can be used to target differentp arts of the same enzyme, thus lead-ing to ad ecrease in activity by binding to the active or allosteric regulatory sites or by alteringi ts surface properties. [30, 31] Similar with other ThDP-dependent enzymes, [32, 33] binding of ThDP with DXS is very tight (K d = 0.114 mm for Deinococcus radiodurans; K d = 3.1 mm for M. tuberculosis). [13] The large active site and high binding affinity forT hDP make it attractive to develop ThDP-competitive peptidic inhibitors.
Combinatorial peptidel ibraries have been used as as ource of ligandsf or av ariety of macromolecules, and differentm ethods are known to select high-affinity bindersf rom such libraries. Oneo ft he most efficient and cost-effective methods to select peptideb indersi sp hage display ( Figure S1 in the Supporting Information). [34] By using this technique,r andom peptides can be expressed on the surfaceo fab acteriophage leadingt ol ibraries with ac omplexity of up to 10 9 different peptides, whichare subjected to several rounds of selectionby which only target-bound phages are retained. The use of phage display allows large libraries of potential inhibitors to be screenedw ithout the need for ac lassical high-throughput screening (HTS) campaign or chemical synthesis of large libraries.
Results and Discussion
To identify peptidic inhibitors for DXS, we chose to exploit phage display by using the model enzyme D. radiodurans DXS, given that it is more stable than M. tuberculosis DXS.
We checked the stability of D. radiodurans DXS both at 4 8C and at room temperature by monitoring its activity for up to 37 hb yu sing IspC as an auxiliary enzyme, which enables spectrophotometric monitoring of the consumption of NADPH. No loss in activity was observed even after 37 ha tr oom temperature. From these initial tests, we concluded that D. radiodurans DXS was stable enough to be used as at arget during the phage-display process. To rule out that we select for support binders, we designed ap hage-display protocol for which the phages were incubated in solution with DXS, and DXS was subsequently recovered by affinity purification by using magnetic beads. We used at wo-step selection approacht oi dentify peptideb inders (Table 1) . Duringt he first step, we screened a fully random M13 bacteriophage peptide library to detect specific sequences that are able to bind any part of the surface of DXS. During this step, we used two types of magnetic beads and several elution buffers to avoid background-selection bias ( Figure S2 ). Analysis of the selected peptides enabled us to design an ew and more stringent library for the second selection step, in which we screened for sequences that could specifically bind to the ThDP-binding site of DXS. We used as olution of ThDP as competitive eluent to select only phages that interact at the ThDP-binding site. Given that unspecific binders are often present after the second round of selection,w e added wild-type M13 phages as competitors:w ild-type phages efficiently competew ithv irus particles expressing the peptide library for unspecific phage-target interactions, and they can be easily filtered out duringp ostsequencing analysis. Both measuresd ecrease the probability of selecting unspecific binders or false positives.
We used ac ommercially availableM 13 library PhD12 (NEB E8111L) for the first phage-display selection against DXS. After three rounds of selection, the analysis of the sequences clearly showedt hat at rue selection had occurred:s everal sequences were repeated multiple times;t his indicated their enrichment in the population (Table 2) . Moreover,w eo bserved an increase in the phage titer during the selection. Event hough no clear motif emerged, we decided to test the mostr ecurrent peptides to investigate their effect on DXS.
We took the four most prevalent sequences (i.e., P1-P4, Ta ble 2) and testedt he synthesized peptides for their inhibito- Table 2 . List of amino-acid sequences obtained after the first round of phage display.
Sequence ID [a] Sequence [b] Peptide ID
[a] Sequencingfile identification number.
[ b] Peptide sequences were generatedb ytranslating the sequenced DNAc onsidering the "amber mutation"c odon usage, that is, the codon TAGw as translated with the amino acid Gln.
[c] Peptide IDs (P1, P2, P3, P4)a re assigned to every sequencet ested.
[d] The value in brackets corresponds to the number of times the sequencew as found to be repeated. ry activity against D. radiodurans DXS. The peptides were dissolved in DMSO (for P1 and P2)o rw ater (for P3 and P4)a nd their inhibitory activities against D. radiodurans DXS were tested by using ac oupled assay with E. coli IspC as the auxiliary enzyme by monitoring the disappearance of NADPH spectrophotometrically at l = 340 nm. [29] So as not to miss out on potentials low binders, we investigated the influence of incubating the peptides with D. radiodurans DXS in Tris·HCl buffer (pH 7.6) for 30 hb oth at room temperature anda t48C. Given that the activity of the enzyme was unchanged in the presence of up to 3% of DMSO, we performed both the directm easurements andt he incubation studies with 2.5 %o fD MSO.
We noticedt hat the peptides dissolved in DMSO gave better results if incubated at 4 8C, whereas peptidesd issolved in water showedt he maximum inhibition at room temperature. The best results were obtained for P2 (50 %i nhibition at 1000 mm after incubation at48Cf or 30 hours) and particularly P3 (47 %i nhibition at 250 mm after incubation at room temperature for 30 h; Ta ble 4). Both P2 and P3 contain two adjacent Ser residues in the sequence:t his Ser-Ser motif might function as af ingerprint for the recognition of the ThDP-binding pocket of D. radiodurans DXS. We performed as econd round of phage display selection protocol by addingacustom-made library taking into account the Ser-Ser motif (see the Experimental Sectionf or furtherd etails). After the selection, the eluted phages were sequenced, and the results are shown in Table 3 . The list contains somes equences that were not present in the commerciall ibrary PhD12,s uch as A10, A06, A01, and D02, whereas A10 is an on-specific protein binder that we found severalt imes in other displays. [35] A06 was repeated several times but did not have aSer-Ser motif. The last two sequences (A01 and D02) might be contaminants given that they were not repeated.A gain, the selection did not result in the emergence of ap articular motif, but ratheri nt he enrichment of specific amino acids with some sequences occurring multiple times.A sa ne xample, P9 was found severalt imes, whereas others were not repeatedb ut containeds ome recurring motifs such as the presence of additional Ser residues and multiple aromatic amino acids within the sequence (marked in bold and underlined in Table 3 ). Moreover,w eo bserved that all the peptides contained at least one Pro residue, preferentially in the central part of the sequence, and aL eu or Ile residue, which might play ar ole in defining conformational preferences.
For ThDP-dependente nzymes such as TK,t he binding pockets of ThDPa nd the acceptor substrate are often in proximity and even share some key amino acids [36] [37] [38] [39] [40] [41] [42] ( Figure S3 ). This might also apply to DXS and its acceptor substrate, d-glyceraldehyde-3-phosphate (d-GAP).T oi dentify both substrate-and cofactor-competitive inhibitors during screening, the concentrations of both ThDP and d-GAP shouldb ea djusted accordingly upon evaluation of the inhibitory activity. D. radiodurans DXS does not afford satisfactory dataq uality under low concentrationso fb oth d-GAP andT hDP.T hus,w ep roposed two rounds of activity evaluation, with assay conditions Ia nd assay conditions II aimed at identifying ThDP-and d-GAP-competitive inhibitors, respectively (Table 4) . We omitted preincubation upon screening for d-GAP-competitive inhibitors, as bindingo f this substrate is neither tight nor irreversible. The resultso f two rounds of activity evaluation of P5-P12 against D. radiodurans DXS are summarized in Table 4 . Peptide P13 from the first phage display also contains the Ser-Ser motif;t herefore, we tested its activity even though the sequence was not enriched.
Duringt he inhibitory evaluation with assay conditions I, P7 showeda nI C 50 value of (13 AE 3) mm,a nd P13 emerged as a double-digit micromolar inhibitor of D. radiodurans DXS [IC 50 = (49 AE 11) mm]a fter incubation at 4 8Cf or 30 hours.T he other peptides did not show any inhibition or only very weaki nhibitory activity (e.g., P10,2 0% inhibition at 1000 mm). We determined the accurate concentration of P7 in solution by UV spectrophotometry by taking advantage of the fact that P7 containsasingle Trpr esidue. As ac onsequence, the IC 50 value was recalculated to (9.5 AE 2.0) mm.U nfortunately,i tw as not possible to determine the accurate concentration of P13 in solution by absorbance measurements owing to the absence of Trpo rT yr residues in the amino-acid sequence.
As for activity evaluation with assay conditions II, P12,t he peptidef ound in eight phage clones after the second round of phage display,h as an IC 50 value of (461 AE 25) mm.T he difference in IC 50 values under the two screening conditions could be an indication that P12 might be d-GAP-competitive.P eptide P7 has an increased IC 50 value of (86 AE 13) mm;t his indicates it might be ThDPc ompetitive. Peptide P13 did not exhibit any activity with assay conditions II, which suggests that it might indeed be slow bindinga nd ThDP competitive or that preincubation might determine its activity.
The use of ac oupleds pectrophotometric assay requires a follow-up assay with the auxiliary enzyme IspC. Therefore, we Table 3 . Peptide sequenceso btained after the round of second phage display.
Sequence ID Sequence
[a] Peptide sequences were generated by translatingt he sequencedD NA considering the "amberm utation"c odon usage, that is, the codon TAG was translated with the amino acid Gln.
[ b] Extra Ser residues and aromatic residuesa re in bold and underlined.
[c] The value in brackets corresponds to the number of times the sequence was found to be repeated.
[d] Indicates ac ontaminant sequence that nonspecifically recognizesa ny protein. tested P7 for its inhibitory potency against E. coli IspC and found that it has an IC 50 value of (490 AE 60) mm.P eptide P13 is not activea gainst E. coli IspC without preincubation but shows an IC 50 value of (266 AE 42) mm after preincubation. Peptide P12 is not active against IspC. AlthoughD XS and IspC catalyzet he first two reactions of the MEP pathway, their structures and functions are very different. The fact that P7 and P13 inhibits both enzymesr aised our concern of nonspecific inhibition. To eliminate false-positive peptides before the MOI study,w ep erformed ad etergent assay,w hich is commonly used to confirm small-molecule aggregators. [43, 44] In parallel, given that inhibition arising from aggregation depends on the amount of enzyme, we compared the inhibitory activity at different DXS concentrations (Table 5) . [45] The results demonstrate that the addition of as malla mount of detergent or an increase in the concentrationo fD XS led to significant attenuation of inhibitory activity for P7 and P13,w hereas P12 was not affected. To corroboratet his result, solutionso fP7 and P13 in assay buffer were investigated by transmission electron microscopy (TEM), and the formation of fibers was observed ( Figure S4 ). Ta ken together,t hree independent experiments showed that P7 and P13 are nonspecific inhibitors that inhibited DXS and IspC by aggregating into fibers and sequestering the enzyme. [46] Even thoughw eu sed low-binding tubes during phage display and 0.05 %T ween 20 in the washing buffer,i tm ight not have been sufficient to exclude all of the false positives. Here, we showed that such fiber-forming nonspecific inhibitors could be conveniently identified by adding 0.01 %T riton X-100 to the assay buffer.T ot he best of our knowledge,w er eport here for the first time the application of the detergenta ssay on peptidic inhibitors. Peptide P12 was confirmed as at rue inhibitora gainst D. radiodurans DXS.
As it is not active against IspC, its MOI could be studied with the coupled assay.F or substrate-competitive inhibitors, the Cheng-Prusoff Equation (1) holds: [47] IC 50 
in which[ S] represents the concentration of the corresponding substrate, and K m is the Michaelis-Menten constanti nt he absence of the inhibitor.B yv arying the initial substrate concentration and plotting IC 50 against (1 + [S]/K m ), ac ompetitive inhibitor shouldg enerate as traight line passing throught he origin, with the slopee quivalent to the inhibition constant, K i . [48, 49] The MOI study of P12 competing with d-GAP is shown in Figure 1 .
The results of cofactora nd pyruvate competition are shown in Figure S5 .
The full kinetic characterization revealed that P12 is a d-GAP-competitive inhibitor,w ith K i = (113 AE 4) mm,a nd noncompetitivew ith respectt ob oth the cofactor ThDPa nd the donor substrate pyruvate. As P12 was washed out using aT hDP buffer,t his result validated our previoush ypothesis:f or DXS, and some other ThDPdependente nzymes, the bindingp ockets of ThDP and the acceptor substrate are closely related, both structurally and functionally,and may not be considered completely separately.
Different from our expectations, we did not identify any ThDP-competitive peptidic inhibitor duringt he second round of phage display.Apossible reasonm ight be that the stringent phage libraryc oincidentally did not contain any hits. Furthermore, the polar character of the diphosphate-binding pocket together with the possibility for metal chelation make the identification of ThDP-competitive inhibitors through phage display challenging.
Conclusions
Herein, we reported the discovery of a d-GAP-competitive peptidic inhibitor, P12,w ith a K i value of (113 AE 4) mm,b yp hage display targetingt he thiamine diphosphate (ThDP)-binding pocket. The expected ThDP-competitive inhibitors were confirmed to be nonspecific false positives by using the detergent assay and transmission electron microscopy.S imilart ow hat was found for other ThDP-dependent enzymes,o ur results indicate that the cofactor-and acceptor-substrate-binding pockets are closely related both structurally and functionally.T his property might provide inspiration to design novel inhibitors for 1-deoxy-d-xylulose-5-phosphate synthase (DXS), targeting the key amino acids sharedb yt he ThDP-and d-GAP-binding pockets.P eptide P12 is the first known peptidic inhibitor of DXS and sets the stage for further rounds of optimization.
Experimental Section
Bacterial strain: E. coli ER2738 (NEB E4104S) [Genotype:
coli in which F' can be selected for by using tetracycline, and it allows Blue/White screening and is an amber mutant strain. It was used for cloning and expression of the phage library,f or titering, and for inoculation of the sequencing plates.
Phage display I: The first phage-display selection protocol was performed by using the commercially available M13 library PhD12 (NEB E8111L) consisting of M13 phages expressing a1 2aa peptide at the Nterminus of each coat protein p3, and as mall Gly-GlyGly-Ser linker was inserted between the peptide and the coat protein to increase the conformational freedom of the exposed peptides and to minimize the contribution of the protein p3 to the overall binding. The schematic sequence of this library is N-term-X 12 -GGGS-p3-C-term. Three rounds of selection were performed in phosphate-buffered saline (PBS;1mL, sodium phosphate 50 mm, NaCl 150 mm,pH7.5) incubating 10E10 phages with D. radiodurans DXS (1 mg) in a2mL protein-low-binding tube for 30 min on ice. For the first two rounds, DXS functionalized with N-hydroxysuccinimide (NHS)-desthiobiotin and Dynabeads MyOne Streptavidin C1 (Invitrogen 65001) were used to capture DXS from the solution. For the third round, to avoid selection of phages against streptavidin and given that D. radiodurans DXS contains an N-terminal Histag, MagneHis Ni Particles (Promega V8560) were used as capturing system. After the incubation step, 0.1 mL of beads were added to the solution, which was mixed in at hermo shaker at 4 8Cf or 15 min. The tube was placed in am agnetic rack to allow for adhesion of the magnetic beads on one side of the tube. Phages expressing DXS binders were retained on the bead surface, and the buffer containing unbound phages was gently discarded from the tube. To remove weakly bound phages further,t he beads were washed with PBST (10 1mLP BS with 0.05 %T ween 20) whilst retaining them using am agnetic rack. The elution of strongly bound phages from the beads was achieved by suspending the beads in the elution buffer (1 mL, 1mm Biotin in PBS for rounds 1a nd 2 and 500 mmi midazole in PBS for round 3). After separation of the beads, the solution containing the eluted phages was used to amplify the selected pool of phages by infecting af resh culture of E. coli ER2738. Infection, production, and purification of the phages were performed by following the manufacturer's manual. Peptides P1-P4 were purchased from CASLO (Lyngby,D enmark) with purity > 97 %according to HPLC.
Library design and cloning: Ac ustom-made library was designed to include the motif Ser-Ser at the Nterminus of the peptide library.T wo oligomers, one coding for the library itself and one used for cloning purposes were designed:
Library oligo:C ATGT TTCGG CCGA(MNN) 9 GGAGG AMNNA GAGTG AGAATAGAAA GGTAC CCGGG Extension primer:CATGC CCGGG TACCT TTCTATTCTC The "library primer" codes for the reverse strand of the library,a nd it includes two flanking regions that contain the restriction site for KpnI/Acc651 and EagI needed for cloning into the M13KE vector. The random part of the peptide sequence is coded by NNK codons (reverse complement of MNN), for which Ni sa ny of the bases, whereas Kr epresents Go rT(thus, Mr epresents Co rA ). An NNK codon can encode for all 20 amino acids but only for one stopcodon:T AG. Combining the use of NNK codons with amber mutant strains such as E. coli ER2738 ensures that the whole library will code for full-length peptides. The "extension primer" is partially complementary with the library-coding oligomer,a nd it was used to generate the double-stranded DNA needed for cloning. The preparations of the library duplex and the cloning were performed as indicated in the manufacturer's manual (NEB E8111L).
Phage display II: Twor ounds of selection were performed by using ac ustom-made phage library.T he schematic sequence of the expressed library is:N -term-XSSX9-GGGS-p3-C-term. TBS (trisbuffered saline, 50 mm Tris·HCl pH 7.5, 150 mm NaCl) was used as incubation buffer,T BST (TBS with 0.05 %T ween 20) was used as washing buffer,M agneHis Ni Particles (Promega V8560) were employed for protein recovery,a nd 1mm ThDP in TBS was used as elution buffer.T hDP was chosen as competitive eluent to elute peptides specifically interacting with the ThDP-binding site of DXS. The same procedure as described for phage display Iw as used with the following modifications:D XS (1 mg) was incubated simultaneously with phages from the new library,p hages from the original PhD-12 library were added to increase sequence complexity, and wild-type phages were supplemented to screen for nonspecific binders. The different phage pools were mixed in a1 :1:1 ratio prior to incubation with the target.
Sequencing: The last elution fractions from the phage display experiments were serially diluted (1:10) and used to infect afresh culture of E. coli ER2738. The infected culture was plated on lysogeny broth (LB)-agar supplemented with tetracycline, isopropyl b-d-1-thiogalactopyranoside (IPTG), and XGal. Blue colonies resulting from phage infection were picked and sent for Sanger sequencing (at GATC Biotech) by using ac ustom-designed M13-specific sequencing primer (GTACA AACTAC AACG CCTGT). Peptides P5-P13 and P7 a-P7 l were purchased from ProteoGenix SAS (Schiltigheim, France) with purity > 95 %according to HPLC.
Gene expression and protein purification of D. radiodurans DXS: Gene expression and protein purification of D. radiodurans DXS were performed as reported in the literature. [13] Spectrophotometric assay for determination of IC 50 values against D. radiodurans DXS (assay conditions I): Direct measurements of the inhibitory activities with the spectrophotometric assay were performed as reported previously. [13] The tolerance of DXS with respect to DMSO concentration was determined by measurement of the reaction velocity in the presence of different concentrations of DMSO. The activity of the enzyme was found to be stable in the presence of up to 3% DMSO. To determine the inhibitory activity of the peptides after incubation, several solutions were prepared containing degassed Tris·HCl (pH 7.6, 100 mm. 300 mL), D. radiodurans DXS (0.79 mm), and different concentrations of each peptide with ad ilution factor of 1:2s tarting, if possible, from 1000 mm.T he solutions were incubated at room temperature or at 4 8Cf or 30 h. Preliminary control experiments showed that the activity of D. radiodurans DXS was unchanged at room temperature or at 4 8Ca fter 30 h. After the incubation time, each incubated solution (95 mL) was transferred to a9 6-well plate, and ab uffer containing Tris·HCl (pH 7.6, 100 mm)a nd d-glyceraldehyde-3-phosphate (4.0 mm)w as added (47.5 mL). The reaction was started by the addition of ab uffer solution (47.5 mL) containing Tris·HCl (pH 7.6, 100 mm), MnCl 2 (16 mm), dithiothreitol (DTT,2 0mm), NADPH (2.0 mm), sodium pyruvate (2.0 mm), ThDP (4.89 mm), and E. coli IspC (8.2 mm). Ac ontrol experiment with the enzyme incubated in Tris·HCl buffer (and DMSO if testing peptides as stock solutions in DMSO) at the same temperature and for the same time was performed in parallel to monitor for potential loss in activity of the enzyme itself, which has never been observed. The reaction was monitored photometrically at room temperature at l = 340 nm by using aS ynergy Mx (Biotek) microplate reader.A bsorbance readings were taken every 30 s. tained Tris·HCl (100 mm,p H7.6), 2.0 mm sodium pyruvate, and 0.2 mm glyceraldehyde-3-phosphate. The dilution series was performed in DMSO (2.4 mL) in each well, starting with a8 0mm DMSO stock solution of P12 and covered the concentration range of 2000 to 2.0 mm.T he reaction was started by adding buffer A( 30 mL) to buffer B( 30 mL). The reaction was monitored photometrically at room temperature at l = 340 nm by using aS ynergy H1 (Biotek) microplate reader.I nitial rate values were evaluated with an onlinear regression method by using the program Dynafit. [50] MOI study: Photometric assays were conducted in transparent flat-bottomed 384-well plates (Nunc MaxiSorp). Michaelis-Menten constants of cofactor and both substrates were determined with a previously reported method. [48, 49] IC 50 values were determined under assay conditions II, with variation of cofactor and substrates, respectively.T he result was repeated in duplicate. The K i value was calculated with SigmaPlot 13.
Gene expression, purification of E. coli IspC, and biochemical evaluation of inhibitory activity against E. coli IspC by spectrophotometric assay: Gene expression and purification of E. coli IspC were performed according to al iterature procedure.
[51] 1-Deoxy-dxylulose-5-phosphate reductoisomerase (IspC) of E. coli bearing a His 6 -tag at its N-terminal end was produced in and purified from recombinant E. coli strain M15 pQEYAEM. Cells were grown in LB medium in as haker at 37 8Cs upplied with ampicillin (100 mg mL À1 ) until the OD 600 value reached 0.4. Thereafter,I PTG was added to a final concentration of 1mm,and the cell suspension was incubated further at 30 8Cw ith vigorous agitation for 16 h. Thereafter,c ells were harvested by centrifugation, washed once with 0.9 %N aCl solution, and frozen at À20 8Cf or storage.
For DXR purification, cell paste (5 g) was resuspended in Tris hydrochloride buffer (25 mL, 50 mm,p H8.0), NaCl (300 mm), 0.02 % NaN 3 ,and 15 %i midazole and disrupted in French Press;c ell debris was centrifuged down, and the supernatant was placed on the top of aN i-NTAc olumn (1 10 cm). After unbound proteins were washed from the column with the same buffer,t he column was developed with an imidazole gradient (15-800 mm). Eluent fractions containing DXS were identified with SDS-polyacrylamide gel electrophoresis, combined, dialyzed versus Tris hydrochloride (30 mm,p H8.0), 30 mm NaCl, 1mm DTT,a nd 0.02 %N aN 3 and concentrated by ultrafiltration and frozen at À80 8Cf or storage.
Spectrophotometric assay for determination of IC 50 values against E. coli IspC: Biochemical evaluation of the inhibitory activity of P7 against E. coli IspC was performed according to ap rotocol reported in the literature. [52] Spectrophotometric inhibition assays with E. coli IspC were performed in 384-well plates with aflat transparent bottom. Assay mixtures (total volume:6 0mL) contained Tris hydrochloride (100 mm,p H7.6), 4mm MnCl 2 ,5 m m DTT, 0.5 mm NADPH, 5% DMSO, 30 nm of recombinant IspC protein, and tested compound. Dilution series (1:3) of potential inhibitors covered the concentration range of 200 to 0.2 mm.T he reaction was started by the addition of 1-deoxyxylulose-5-phosphate (DXP) to af inal concentration of 0.5 mm.T he reaction was monitored photometrically (l = 340 nm) at room temperature (20-23 8C) in a microplate reader (SpectraMax M5, Molecular Devices, USA). Initial rate values were evaluated by using the nonlinear regression method with the program Dynafit. [50] ChemBioChem 2018, 19,58-65 www.chembiochem.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim
